Syntara shows encouraging first signals it can impact the path to Parkinson's
Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence that the company’s novel anti-inflammatory therapy may be targeting a key biological process linked to the development of Parkinson’...
Market Cap $2.064B
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 16.10pm 08/07/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | $16.43 | Day High | $16.74 | Day Low | $16.26 | |||
| Daily Volume | 394572 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | $16.73 | 2465 | 0 | $16.74 | 1085 | |
Directors & Senior Management
| Dr. Clive Blower | Chief Operations Officer |
| Mr. Daryl Dekarske | Chief Regulatory Officer |
| Ms. Dianne M. Angus | Independent Non-Executive Director |
| Mr. Gerry Zhao | Chief Business Officer |
| Dr. Jenny Lee Harry | Independent Non-Executive Director |
| Mr. Joe Basile | Independent Non-Executive Director |
| Mr. Jonathan Charles Pilcher | CEO, MD & Executive Director |
| Ms. Lauren Frazer | CFO & Company Secretary |
| Mr. Lawrence Glass | Chief Science Officer |
| Dr. Liza A. Squires | Chief Medical Officer |
| Mr. Patrick Donald Davies | Independent Non-Executive Chairman |
Data source: ADVFN
